Scott J. Cross, MD
Specialist
5900 Lake Wright Dr
Norfolk, VA 23502
Who else practices at this address →
Norfolk city is a federal dental shortage area. About shortage areas
- Medicare participating
At a glance
- Medical school
- Ohio State University College of Medicine (1997)
- Years since graduation
- 29
- In the NPI registry since
- 2005
- Medicare patients seen, 2024
- 822
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1997Medical school: Ohio State University College of Medicine
- 2005Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Specialist primary
VA license 0101234754
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Sentara Norfolk General Hospital Norfolk, VA
- Sentara Leigh Hospital Norfolk, VA
- Sentara Virginia Beach General Hospital Virginia Beach, VA
- Sentara Princess Anne Hospital Virginia Beach, VA
- Sentara Obici Hospital Suffolk, VA
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 822
- Services billed
- 194,876
- Patients’ average age
- 74
| Service | Times | Patients |
|---|---|---|
| Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | 19,890 | 13 |
| Injection, daratumumab, 10 mg and hyaluronidase-fihj | 19,800 | 15 |
| Injection, darbepoetin alfa, 1 microgram (non-esrd use) | 10,160 | 14 |
| Injection, azacitidine, 1 mg | 9,400 | 12 |
| Injection, pembrolizumab, 1 mg | 6,400 | 11 |
| Injection, denosumab, 1 mg | 5,460 | 14 |
| Injection, rituximab-pvvr, biosimilar, (ruxience), 10 mg | 3,218 | 11 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 1,965 | 460 |
| Injection, dexamethasone sodium phosphate, 1 mg | 1,867 | 47 |
| Blood test, comprehensive group of blood chemicals | 1,383 | 403 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Acyclovir Other prescribers in Norfolk, VA | 116 |
| Eliquis (apixaban) Other prescribers in Norfolk, VA | 76 |
| Dexamethasone Other prescribers in Norfolk, VA | 40 |
| Lenalidomide | 38 |
| Levofloxacin Other prescribers in Norfolk, VA | 34 |
| Xarelto (rivaroxaban) Other prescribers in Norfolk, VA | 33 |
| Anastrozole Other prescribers in Norfolk, VA | 33 |
| Prednisone Other prescribers in Norfolk, VA | 33 |
| Pomalyst (pomalidomide) | 30 |
| Ondansetron Odt (ondansetron) Other prescribers in Norfolk, VA | 26 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 2 companies reported 2 payments worth $167 in total to this clinician.
| Array Biopharma Inc | $150 |
|---|---|
| Csl Behring | $17.48 |
| Compensation for services other than consulting (speaking, faculty) | $150 |
|---|---|
| Food and Beverage | $17.48 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Array Biopharma Inc Jul 19, 2025 | Compensation for services other than consulting (speaking, faculty) LORBRENA; BRAFTOVI; MEKTOVI · ONCOLOGY | $150 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 8 industry-funded studies in 2025, from 3 companies. The companies reported $249,319 in research payments for these studies, mostly to the institutions running them.
- Ph3 study of Pola R CHP Glofit vs PolaR CHP in 1L DLBCL
Genentech, Inc. - A Phase 3 Randomized Study Comparing Teclistamab in Combination with Daratumumab SC and Lenalidomide (Tec-DR) versus Daratumumab SC, Lenalidomide, and Dexamethasone (DRd) in Participants with Newly Diagnosed Multiple …
Janssen Research & Development, LLC - A Study of Daratumumab Plus Lenalidomide Versus Lenalidomide Alone as Maintenance Treatment in Participants With Newly Diagnosed Multiple Myeloma Who Are Minimal Residual Disease Positive After Frontline Autologous St…
Janssen Research & Development, LLC - Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) Versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)
E.r. Squibb & Sons, L.l.c. · Active, not recruiting · NCT04975997 - A Phase 3 Randomized Study Comparing Teclistamab in Combination with Daratumumab SC and Lenalidomide (Tec-DR) versus Daratumumab SC, Lenalidomide, and Dexamethasone (DRd) in Participants with Newly Diagnosed Multiple …
Janssen Research & Development, LLC - Lenalidomide Plus Rituximab Followed by Lenalidomide Versus Rituximab Maintenance for Relapsed/Refractory Follicular, Marginal Zone or Mantle Cell Lymphoma.
E.r. Squibb & Sons, L.l.c. · Completed · NCT01996865 - A Phase 3 Randomized Study Comparing Teclistamab Monotherapy versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants with Relapsed or Refractory Multiple Myeloma who hav…
Janssen Research & Development, LLC - Expanded Access Protocol (EAP) of subjects receiving nonconforming lisocabtagene maraleucel that is out of specification (OOS) for commercial release
E.r. Squibb & Sons, L.l.c.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.